Sector News

J&J expands COVID-19 vaccine pact with Catalent for finishing work at Italian facility

July 7, 2020
Life sciences

Johnson & Johnson has been on a manufacturing deal spree as it nears human trials for its COVID-19 vaccine hopeful. On the same day it inked a $480 order from a Maryland CDMO, J&J announced it would expand its pact with another manufacturer to scale up production as fast as possible.

J&J has expanded its COVID-19 vaccine manufacturing pact with New Jersey-based Catalent to include work at the CDMO’s Anagni, Italy facility, a J&J spokesman said Monday.

New Jersey-based J&J initially tapped Catalent in April to reserve fill-finish capacity for its COVID-19 shot at its Bloomington, Indiana plant. As part of that deal, Catalent agreed to hire an additional 300 workers at the plant starting this month, with the goal of reaching 24/7 manufacturing schedules by January.

In an email, J&J didn’t specify what work Catalent would perform at the Anagni site, but the CDMO previously signed a deal with British drugmaker AstraZeneca to perform fill-finish and packaging duties for the University of Oxford’s adenovirus-based COVID-19 vaccine, AZD1222.

“The latest agreement with Catalent Pharma Solutions in Italy is a continuation of our partnership and represents progress in our overall efforts,” the drugmaker said.

J&J didn’t disclose the financial terms of the deal. A Catalent spokesman could not be reached for comment by press time.

During a visit to the Anagni site Monday, Italian Health minister Roberto Speranz indicated J&J’s vaccine would be completed at the 305,000-square-foot site, Reuters reported.

In mid-June, Catalent and AstraZeneca reached a deal for finish-fill duties at the Anagni site, with Catalent pledging to produce “hundreds of millions of doses” beginning in August 2020 and potentially running through March 2022 if the vaccine receives full regulatory approval.

On Monday, J&J signed a five-year supply deal with Maryland-based Emergent BioSolutions to produce even more of its COVID-19 shot. The first two years of that deal are valued at $480 million, with doses provided as needed in the final three years.

As the initial step in what was pitched as the “first in a series” of manufacturing deals in March, J&J tapped Emergent to help boost production of its shot, which the company hopes to move into phase 1/2 trials later this month.

As part of the deal, J&J pledged to expand its own capacity for producing the vaccine with Emergent sharing its “molecule-to-market” manufacturing know-how. Emergent also reserved capacity at its Bayview Baltimore facility to support a potential commercial rollout of J&J’s shot beginning as early as 2021, should it nab an approval.

By: Kyle Blankenship

Source: Fierce Pharma

Related News

August 4, 2020

Lilly starts phase 3 test of COVID-19 antibody in nursing homes

Life sciences

Eli Lilly has started a phase 3 trial to evaluate whether its antibody LY-CoV555 stops the residents of nursing homes from developing COVID-19. Lilly has created customized mobile research units to run […]

August 4, 2020

AbbVie, Amgen and Takeda test anti-inflammatory drugs in joint COVID-19 study

Life sciences

The drug industry has come together in unprecedented collaborative efforts to tackle COVID-19. Now, as part of an R&D alliance, three big drugmakers are running a joint clinical trial to […]

July 30, 2020

Roche bets $120M on UCB’s anti-tau Alzheimer’s antibody

Life sciences

As Roche plugs away at its anti-amyloid treatment for Alzheimer’s disease, it’s adding a tau-targeting treatment to the mix. The Swiss pharma is handing over $120 million upfront for the […]